The updated 2022 systematic evidence review4 focuses specifically on longer-term (3–7 years, and more than 7 years) follow-up studies, including data on efficacy, effectiveness and safety of multidose and single dose regimens of inactivated and live attenuated hepatitis A vaccines in children, and adults vaccinated during childhood. The evidence generated from the 2012 systematic review was also considered.
This document replaces the 2012 WHO position paper on hepatitis A vaccines.5 It contains off-label recommendations.

  • Position paper
  • Hepatitis A